基于血清蛋白质组分析技术鉴定鼻咽癌ENO1自身抗体诊断分子标志物

Serum proteomic-based analysis identifying autoantibody against ENO1 as a potential diagnostic biomarker in nasopharyngeal carcinoma

目的筛选鉴定鼻咽癌自身抗体分子诊断标志物。方法应用鼻咽癌CNE2细胞蛋白进行血清蛋白质组分析筛选鼻咽癌潜在的自身抗体分子标志物。于2014年7月至2015年1月在汕头大学医学院附属肿瘤医院选取50例鼻咽癌患者和80例健康体检者,采用酶联免疫吸附试验(ELISA)验证筛选的自身抗体在两组血清中的水平,采用受试者工作特征曲线(ROC)评价诊断效能。结果血清蛋白质组分析结果显示,针对烯醇化酶1(ENO1)的自身抗体在鼻咽癌患者血清中出现阳性反应。ELISA结果显示,鼻咽癌患者血清ENO1自身抗体水平明显高于健康体验者[0.165(0.088,0.378)vs.0.100(0.054,0.117),Z=4.077,P<0.001]。ROC曲线显示,当血清ENO1自身抗体取诊断临界值为0.164时,其诊断鼻咽癌的敏感性为52.0%,特异性为90.0%。在早期鼻咽癌中,ENO1自身抗体阳性率为75.0%。结论血清ENO1自身抗体是鼻咽癌潜在的血清诊断标志物。

Objective To screen and identify autoantibody biomarker to diagnose patients with nasopharyngeal carcinoma(NPC).Methods Candidate autoantibodies against tumor-associated antigens were identified from NPC CNE2 cells using serological proteome analysis.Levels of candidate autoantibody biomarkers were measured by enzyme-linked immunosorbent assay(ELISA)in 50 patients with NPC and 80 normal controls recruited from the Cancer Hospital of Shantou University Medical College between July 2014 and January 2015.Receiver operating characteristic curve(ROC)was employed to evaluate diagnostic efficacy.Results Serological proteome analysis showed that sera from patients with NPC yielded a positive spot,of which was identified as enolase 1(ENO1).ELISA results showed that the level of serum autoantibody against ENO1 in patients with NPC was significantly higher than that in normal controls[0.165(0.088,0.378)vs.0.100(0.054,0.117),Z=4.077,P<0.001].With the optimum diagnostic cutoff of 0.164,ROC curve showed the diagnostic sensitivity and specificity of autoantibodies against ENO1 were 52.0%and 90.0%,respectively.Measurement of autoantibody against ENO1 demonstrated a positive rate of 75.0%for early stage NPC.Conclusion Autoantibody against ENO1 may be a potential diagnostic biomarker for NPC.